Novartis

Dr. Stephen Chen named chairman, CEO of Amarillo

Monday, February 27, 2012 10:10 AM

Amarillo Biosciences, a U.S. biotechnology firm, has appointed Dr. Stephen T. Chen CEO and chairman of the board.

More... »


J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

More... »


Novartis wins PharmaTimes Clinical Company of the Year

Friday, February 24, 2012 10:48 AM

Novartis Pharmaceuticals won of the overall prize for PharmaTimes Clinical Company of the Year at an awards ceremony in London on February16.

More... »

Enanta, Novartis collaborate to advance Hep C inhibitor

Wednesday, February 22, 2012 01:53 PM

Enanta Pharmaceuticals, a developer of best-in-class small molecule drugs in the infectious disease field, has formed an exclusive collaboration and license agreement with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, a hepatitis C virus inhibitor.

More... »

Unigene appoints Mayes and Pepper to biotechnologies SBU

Friday, February 10, 2012 11:48 AM

Unigene Laboratories announced the expansion of its biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes to chief business officer and appointment of Jane Pepper to senior director, business development.

More... »

Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

More... »

FDA approves Gleevec for rare gastrointestinal cancer

Thursday, February 2, 2012 08:32 AM

The FDA has granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

Novartis to restructure, cut 1,960 jobs

Thursday, January 19, 2012 09:30 AM

Novartis has announced plans to strengthen its long-term competitive position and reduce its cost base with a restructuring of U.S. operations.

More... »

FDA says Opioids may be found in Novartis OTC drugs

Wednesday, January 11, 2012 11:25 AM

The FDA has released an advisory regarding the Novartis recall due to the mixed bottling of products. While previous reports suggested that the OTC drugs NoDoz, Excedrin, Bufferin and Gas-X had simply been mixed with each other, the FDA now is warning patients that high-powered, prescription-only opioid drugs may have found their way into Novartis OTC packaging.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs